{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:26:08Z","timestamp":1761765968339},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To report our institutional experience using definitive chemoradiation via whole bladder (WB) and partial bladder (PB) treatment in muscle-invasive bladder cancer. Combining intensity-modulated radiation therapy with image-guidance can improve the therapeutic ratio.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Retrospective analysis of 26 patients with clinical stage T2-4 N0-2 M0 urothelial cancer treated in 2009 to 2012; 16 received WB radiation and 10 received PB radiation. PB\/tumor boost volume included visibly thickened bladder wall or tumor localized on cystoscopy. WB radiation delivered 45 to 50.4 Gy to bladder\/lymph nodes, then sequential 19.8 to 21.6 Gy tumor boost (1.8 Gy\/fx). PB radiation was 45 to 50 Gy to lymph nodes (1.8 to 2 Gy\/fx) and simultaneous integrated boost to 55 to 62.5 Gy to tumor only (2.2 to 2.5 Gy\/fx). The primary endpoint was local control, defined as no muscle-invasive recurrence. Secondary endpoints were overall survival, toxicity, and cost.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mean age was 77 and median follow-up was 20 months. Freedom from local recurrence was 86% at 2 years (PB 100%, WB 77%). Overall survival was 80% at 1 year (PB 88%, WB 75%), and 55% at 2 years (PB 70%, WB 48%, <jats:italic toggle=\"yes\">P<\/jats:italic>=0.38). Failure was predominantly distant. Toxicities were minimal (3 late grade 3 ureteral, 1 acute grade 4 renal), and all resolved. No cystectomies were performed for toxicity. Hypofractionation reduces treatment time and costs by one third.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Image-guided hypofractionated PB radiation provides local control with similar survival to WB therapy, with minimal toxicity. Hypofractionation also offers time and cost advantages. Our results need to be validated in a larger, multi-institutional cohort.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000237","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T12:12:00Z","timestamp":1446639120000},"page":"107-114","source":"Crossref","is-referenced-by-count":14,"title":["Whole Versus Partial Bladder Radiation"],"prefix":"10.1097","volume":"41","author":[{"given":"Jung J.","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Kupelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherri","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/00005650-199508000-00007","article-title":"Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis","volume":"33","author":"Riley","year":"1995","journal-title":"Med Care"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2010.09537.x","article-title":"Life and death of SPARE (Selective bladder Preservation Against Radical Excision): reflections on why the SPARE trial closed","volume":"106","author":"Huddart","year":"2010","journal-title":"BJU Int"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/00365590310020060","article-title":"Early and late treatment-related morbidity following radical cystectomy","volume":"38","author":"Knap","year":"2004","journal-title":"Scand J Urol Nephrol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.1992.tb15660.x","article-title":"Male and female sexual function and activity following ileal conduit urinary diversion","volume":"70","author":"Nordstrom","year":"1992","journal-title":"Br J Urol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0302-2838(02)00581-X","article-title":"A study of the morbidity, mortality, and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire","volume":"43","author":"Chahal","year":"2003","journal-title":"Eur Urol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0167-8140(86)80059-7","article-title":"The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy","volume":"7","author":"Duncan","year":"1986","journal-title":"Radiother Oncol"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/01.ju.0000093721.23249.c3","article-title":"Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors","volume":"170","author":"Zietman","year":"2003","journal-title":"J Urol"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation Therapy Oncology Group Protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0090-4295(01)01219-5","article-title":"Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder","volume":"58","author":"Zietman","year":"2001","journal-title":"Urology"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJM199004193221607","article-title":"Biology and management of bladder cancer","volume":"322","author":"Raghavan","year":"1990","journal-title":"NEJM"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijrobp.2003.10.018","article-title":"Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy","volume":"59","author":"Cowan","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijrobp.2013.06.2044","article-title":"Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 Trial (CRUK\/01\/004)","volume":"87","author":"Huddart","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1080\/02841860802251575","article-title":"The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy","volume":"48","author":"S\u00f8ndergaard","year":"2009","journal-title":"Acta Oncol"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1001\/jama.1989.03430200123038","article-title":"Clinical economics, a guide to the economic analysis of clinical practices","volume":"262","author":"Eisenberg","year":"1989","journal-title":"JAMA"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/S1677-5538.IBJU.2015.01.06","article-title":"Risk groups in bladder cancer patients treated with radical cystectomy","volume":"41","author":"Mallen","year":"2015","journal-title":"Int Braz J Urol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0090-4295(99)80262-3","article-title":"Bladder-sparing multimodality treatment of muscle-invasive bladder cancer: a five-year follow-up","volume":"46","author":"Given","year":"1995","journal-title":"Urology"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0167-8140(98)00089-9","article-title":"Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment","volume":"49","author":"Moonen","year":"1998","journal-title":"Radiother Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1464-410X.1986.tb09093.x","article-title":"Results of surgery following radical radiotherapy for invasive bladder cancer","volume":"58","author":"Quilty","year":"1986","journal-title":"Br J Urol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.urolonc.2012.07.005","article-title":"Neoadjuvant chemotherapy with gemcitabine\/cisplatin vs. methotrexate\/vinblastine\/doxorubicin\/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California","volume":"31","author":"Fairey","year":"2013","journal-title":"Urol Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/cncr.20654","article-title":"Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy","volume":"101","author":"Danesi","year":"2004","journal-title":"Cancer"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ijrobp.2013.11.005","article-title":"Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer","volume":"88","author":"Turgeon","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1748-717X-6-75","article-title":"Intensity modulated radiotherapy for elderly bladder cancer patients","volume":"6","author":"Hsieh","year":"2011","journal-title":"Radiat Oncol"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201802000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:01:21Z","timestamp":1693710081000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201802000-00001"}},"subtitle":["Use of an Image-guided Hypofractionated IMRT Bladder-preservation Protocol"],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000237","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}